ATE243709T1 - Neue inhibitoren und herabregulierende substanzen für matrix-metalloproteinasen - Google Patents

Neue inhibitoren und herabregulierende substanzen für matrix-metalloproteinasen

Info

Publication number
ATE243709T1
ATE243709T1 AT99910394T AT99910394T ATE243709T1 AT E243709 T1 ATE243709 T1 AT E243709T1 AT 99910394 T AT99910394 T AT 99910394T AT 99910394 T AT99910394 T AT 99910394T AT E243709 T1 ATE243709 T1 AT E243709T1
Authority
AT
Austria
Prior art keywords
inhibitors
matrix metalloproteinases
mmp
regulators
novel
Prior art date
Application number
AT99910394T
Other languages
English (en)
Inventor
Erkki Koivunen
Timo Sorsa
Tuula Salo
Original Assignee
Ctt Cancer Targeting Tech Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ctt Cancer Targeting Tech Oy filed Critical Ctt Cancer Targeting Tech Oy
Application granted granted Critical
Publication of ATE243709T1 publication Critical patent/ATE243709T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99910394T 1998-03-18 1999-03-17 Neue inhibitoren und herabregulierende substanzen für matrix-metalloproteinasen ATE243709T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI980604A FI980604A0 (fi) 1998-03-18 1998-03-18 Nya matrismetalloproteinasinhibitorer och -regulatorer
PCT/FI1999/000204 WO1999047550A1 (en) 1998-03-18 1999-03-17 Novel matrix metalloproteinase inhibitors and down-regulators

Publications (1)

Publication Number Publication Date
ATE243709T1 true ATE243709T1 (de) 2003-07-15

Family

ID=8551311

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99910394T ATE243709T1 (de) 1998-03-18 1999-03-17 Neue inhibitoren und herabregulierende substanzen für matrix-metalloproteinasen

Country Status (12)

Country Link
US (1) US6624144B1 (de)
EP (1) EP1071704B1 (de)
JP (1) JP2002506881A (de)
AT (1) ATE243709T1 (de)
AU (1) AU2936599A (de)
CA (1) CA2323239C (de)
DE (1) DE69909076T2 (de)
DK (1) DK1071704T3 (de)
ES (1) ES2203088T3 (de)
FI (1) FI980604A0 (de)
PT (1) PT1071704E (de)
WO (1) WO1999047550A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9907908D0 (en) * 1999-04-07 1999-06-02 Bataille Regis Organic compounds
DE10020447A1 (de) * 2000-03-31 2001-10-11 Henkel Kgaa Verwendung von Protease-Inhibitoren in der Kosmetik und Pharmazie
EP1174129A1 (de) * 2000-07-17 2002-01-23 Zenner, Hans Peter, Prof. Dr. med. Verwendung eines Matrix-Metalloproteinase-Inhibitors zur Behandlung von Krebs
US7041787B2 (en) * 2000-12-29 2006-05-09 Kimberly-Clark Worldwide, Inc. Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases
FI113840B (fi) * 2001-03-26 2004-06-30 Ctt Cancer Targeting Tech Oy Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa
US6906036B2 (en) * 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US20050277623A1 (en) * 2001-12-20 2005-12-15 Hanauske-Abel Hartmut M Treatment for averting or delaying premature delivery
CN1633501B (zh) * 2002-01-08 2010-10-27 迈克尔·R·拉尔布 表达civps或内含肽修饰蛋白的转基因植物及其制备方法
US20040224378A1 (en) * 2002-06-07 2004-11-11 Athersys, Inc. Methods for using ADAMTS-12, an integrin and metalloprotease with thrombspondin motifs
FI20021726A0 (fi) * 2002-09-27 2002-09-27 Ctt Cancer Targeting Tech Oy Menetelmä peptidien tuottamiseksi
CN1314704C (zh) * 2002-11-20 2007-05-09 中国人民解放军军事医学科学院放射与辐射医学研究所 基质金属蛋白酶2的小肽抑制剂
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
ES2537514T3 (es) 2003-04-04 2015-06-09 Incyte Corporation Composiciones, métodos y kits relacionados con la escisión de HER-2
WO2005019247A2 (en) * 2003-08-15 2005-03-03 Board Of Regents, The University Of Texas System Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy
FI20040572A0 (fi) * 2004-04-23 2004-04-23 Ctt Cancer Targeting Tech Oy Matriisi-metalloproteinaasin aktiviteetin inhibiittorit
FR2932182A1 (fr) * 2008-06-10 2009-12-11 Commissariat Energie Atomique Cyclopeptides utilisables en tant qu'inhibiteurs d'enzymes proteases du type mmp
KR101363455B1 (ko) 2011-09-09 2014-02-21 (주)케어젠 매트릭스 메탈로프로테아제 활성 억제 펩타이드 및 이의 용도
CN108484729B (zh) * 2018-03-23 2019-09-17 中国药科大学 一种基质金属蛋白酶9的多肽抑制剂及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666897A (en) 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
CZ288436B6 (en) * 1994-10-05 2001-06-13 Darwin Discovery Ltd Peptidyl derivatives, their therapeutic use as inhibitors of metalloproteinases and pharmaceutical preparation in which they are comprised
US5652227A (en) 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals

Also Published As

Publication number Publication date
WO1999047550A1 (en) 1999-09-23
FI980604A0 (fi) 1998-03-18
JP2002506881A (ja) 2002-03-05
US6624144B1 (en) 2003-09-23
ES2203088T3 (es) 2004-04-01
CA2323239A1 (en) 1999-09-23
EP1071704B1 (de) 2003-06-25
DE69909076T2 (de) 2004-05-06
AU2936599A (en) 1999-10-11
CA2323239C (en) 2008-04-15
DE69909076D1 (de) 2003-07-31
EP1071704A1 (de) 2001-01-31
PT1071704E (pt) 2003-11-28
DK1071704T3 (da) 2003-10-20

Similar Documents

Publication Publication Date Title
ATE243709T1 (de) Neue inhibitoren und herabregulierende substanzen für matrix-metalloproteinasen
Overall et al. Demonstration of tissue collagenase activity in vivo and its relationship to inflammation severity in human gingiva
Shankavaram et al. Monocyte membrane type 1-matrix metalloproteinase: prostaglandin-dependent regulation and role in metalloproteinase-2 activation
Wang et al. Natural products as a gold mine for selective matrix metalloproteinases inhibitors
DK1268847T3 (da) Ubiquitin-ligaseassay
NO963499L (no) Hydroksaminsyre- og karboksylsyrederivater, fremgangsmåte for deres fremstilling og anvendelse derav
ATE138076T1 (de) Matritzenmetalloproteinasepeptide, ihre wirkung in diagnose und therapie
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
BR0010555A (pt) Inibidores de neuraminidases
BR9813651A (pt) Compostos antipicornavirais e métodos para o seu uso e preparação
BR0211118A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
BR9916004A (pt) Inibidores de proteinase c de pró-colágeno
BR9815469A (pt) Inibidores de protease
ATE309264T1 (de) Peptidyl-2-amino-1hydroxyalkansulfonsäuren als cystein-protease-inhibitoren
Song et al. Inhibitory effect of procyanidin oligomer from elm cortex on the matrix metalloproteinases and proteases of periodontopathogens
ATE494363T1 (de) Neue cyclooxygenase-varianten und verwendungsverfahren
ATE282607T1 (de) Tryptase-inhibitoren
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
BR0214359A (pt) Método para tratar ou prevenir o mal de alzheimer e uma doença e para tratar um paciente que tem, ou para prevenir que um paciente adquira uma doença ou condição, para inibir a atividade de beta-secretase, a clivagem de um isotipo de proteìna de precursor amilóide e a produção de peptìdeo e de placa beta-amilóide e para produzir um complexo de beta-secretase, uso de um composto e, composição
EP1509220A4 (de) Pharmazeutische zusammensetzung zur behandlung von seborrhoe mit 4-hydroxy-5-methoxy-4-2-methyl-3(3-methyl-2-butenyl)-2-oxiranyl -1-oxaspiro 2,5 octan-6-on
NO20025124D0 (no) Metode
Sandya et al. Multiple matrix metalloproteinases in type II collagen induced arthritis
ATE295724T1 (de) Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse
Nakamura et al. 4-Methylumbelliferone induces the expression of membrane type 1-matrix metalloproteinase in cultured human skin fibroblasts
BR0114258A (pt) Esteróides de 17alfa-fluoroalquila, processo para sua produção e composições farmacêuticas que contêm estes compostos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1071704

Country of ref document: EP

REN Ceased due to non-payment of the annual fee